Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01157234 · ClinicalTrials.gov registry record · Phase 4

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

A Phase 4 study, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
32
Enrollment target

NCT01157234 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01157234, a Phase 4 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
32 participants
Enrollment target

Study Summary

This study will investigate the blood pressure lowering efficacy of nebivolol among renal transplant recipients who are on calcineurin inhibitors which are believed to contribute to hypertension by sympathetic nervous system (SNS) activation and decreased prostaglandin and nitric oxide production. Hypotheses: 1. There is a significant difference in the effect of 12 months of Nebivolol versus Metoprolol treatment on the plasma nitric oxide level of hypertensive renal transplant patients. 2. There is a significant difference in the effect of 12 months of Nebivolol versus Metoprolol treatment on the estimated glomerular filtration rate of hypertensive renal transplant patients. 3. There is a significant difference in the effect of 12 months of Nebivolol versus Metoprolol treatment on the systolic, diastolic and mean arterial blood pressures of hypertensive renal transplant patients.

Interventions

  • DRUG Nebivolol
  • DRUG Metoprolol

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2010-07
Est. Completion 2014-07
Phase Phase 4

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT01157234

The ClinicalTrials.gov registry entry for NCT01157234 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Nebivolol is the first listed.

NCT01157234 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01157234 about?

NCT01157234 is a clinical study titled "Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients". This study will investigate the blood pressure lowering efficacy of nebivolol among renal transplant recipients who are on calcineurin inhibitors which are believed to contribute to hypertension by sympathetic nervous system (SNS) activation and decreased prostaglandin and nitric oxide production. H...

What is the current status of trial NCT01157234?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2010-07. Estimated completion is 2014-07.

What interventions are being tested in trial NCT01157234?

The interventions under investigation include: Nebivolol (DRUG), Metoprolol (DRUG).

Who is sponsoring clinical trial NCT01157234?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.